Register Login

TANGO THERAPEUTICS, INC. (TNGX)

SymbolTNGX
NameTANGO THERAPEUTICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address201 BROOKLINE AVE.,SUITE 901, BOSTON, Massachusetts, 02215, United States
Telephone+1 857 320-4900
Fax—
Email—
Websitehttps://www.tangotx.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001819133
Description

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.

Additional info from NASDAQ:
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.

2026-09-01 11:00

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Read more
2026-08-14 17:43

New Form SCHEDULE 13G/A - Tango Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001916761-26-000008 <b>Size:</b> 14 KB

Read more
2026-08-14 17:19

New Form SCHEDULE 13G/A - Tango Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352271 <b>Size:</b> 16 KB

Read more
2026-08-14 15:13

New Form SCHEDULE 13G - Tango Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000886982-26-000510 <b>Size:</b> 18 KB

Read more
2026-08-14 12:05

New Form SCHEDULE 13G/A - Tango Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000919574-26-005265 <b>Size:</b> 9 KB

Read more
2026-08-14 09:24

New Form SCHEDULE 13G/A - Tango Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000908834-26-000425 <b>Size:</b> 49 KB

Read more
2026-08-12 13:02

New Form SCHEDULE 13G/A - Tango Therapeutics, Inc. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0000919574-26-004954 <b>Size:</b> 12 KB

Read more
2026-08-11 21:13

(99% Neutral) TANGO THERAPEUTICS, INC. (TNGX) Announces Business Combination

Read more
2026-08-11 18:11

New Form 424B5 - Tango Therapeutics, Inc. <b>Filed:</b> 2026-08-11 <b>AccNo:</b> 0001193125-26-344989 <b>Size:</b> 759 KB

Read more
2026-08-11 11:20

(10% Negative) TANGO THERAPEUTICS, INC. (TNGX) Reports Q3 2026 Financial Results

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT06922591 Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination … Phase1 PDAC Recruiting 2025-05-31 2027-12-01 ClinicalTrials.gov
NCT06810544 Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in … Phase1 Non Small Cell Lung Cancer Recruiting 2025-03-24 2027-09-30 ClinicalTrials.gov
NCT06065059 Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA … Phase1 Breast Cancer Terminated 2023-12-08 2024-05-22 ClinicalTrials.gov
NCT05887492 Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors Phase1 Non Small Cell Lung Cancer Active_Not_Recruiting 2023-06-12 2026-09-01 ClinicalTrials.gov
NCT05732831 Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors Phase1 Locally Advanced Solid Tumor Recruiting 2023-05-26 2026-09-01 ClinicalTrials.gov
NCT05275478 Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors Phase1 Locally Advanced Solid Tumor Terminated 2022-03-23 2025-12-30 ClinicalTrials.gov
Total clinical trials: 6
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Cancer ACTIVE_NOT_RECRUITING NCT05887492
TNG260 Other Phase PHASE1 Non Small Cell Lung Cancer ACTIVE_NOT_RECRUITING NCT05887492
gemcitabine/nab-paclitaxel Other Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 Other Phase PHASE1 PDAC RECRUITING NCT06922591
TNG462 Other Phase PHASE1 PDAC RECRUITING NCT06922591
gemcitabine/nab-paclitaxel Other Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 Other Phase PHASE1 PDAC RECRUITING NCT06922591
TNG462 Other Phase PHASE1 PDAC RECRUITING NCT06922591
gemcitabine/nab-paclitaxel Other Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 Other Phase PHASE1 PDAC RECRUITING NCT06922591
TNG462 Other Phase PHASE1 PDAC RECRUITING NCT06922591
gemcitabine/nab-paclitaxel Other Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 Other Phase PHASE1 PDAC RECRUITING NCT06922591
TNG462 Other Phase PHASE1 PDAC RECRUITING NCT06922591
gemcitabine/nab-paclitaxel Other Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 Other Phase PHASE1 PDAC RECRUITING NCT06922591
TNG462 Other Phase PHASE1 PDAC RECRUITING NCT06922591
gemcitabine/nab-paclitaxel Other Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 Other Phase PHASE1 PDAC RECRUITING NCT06922591
TNG462 Other Phase PHASE1 PDAC RECRUITING NCT06922591
gemcitabine/nab-paclitaxel Other Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 Other Phase PHASE1 PDAC RECRUITING NCT06922591
TNG462 Other Phase PHASE1 PDAC RECRUITING NCT06922591
gemcitabine/nab-paclitaxel Other Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 Other Phase PHASE1 PDAC RECRUITING NCT06922591
TNG462 Other Phase PHASE1 PDAC RECRUITING NCT06922591
Olaparib Other Phase PHASE1 Breast Cancer TERMINATED NCT06065059
TNG348 Other Phase PHASE1 Breast Cancer TERMINATED NCT06065059
Pembrolizumab Other Phase PHASE1 Non Small Cell Lung Cancer RECRUITING NCT05887492
TNG260 Other Phase PHASE1 Non Small Cell Lung Cancer RECRUITING NCT05887492
abemaciclib Other Phase PHASE1 Non Small Cell Lung Cancer RECRUITING NCT06810544
TNG456 Other Phase PHASE1 Non Small Cell Lung Cancer RECRUITING NCT06810544
TNG908 Other Phase PHASE1 Locally Advanced Solid Tumor TERMINATED NCT05275478
Pembrolizumab Other Phase PHASE1 Locally Advanced Solid Tumor RECRUITING NCT05732831
TNG462 Other Phase PHASE1 Locally Advanced Solid Tumor RECRUITING NCT05732831
gemcitabine/nab-paclitaxel Other Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 Other Phase PHASE1 PDAC RECRUITING NCT06922591
TNG462 Other Phase PHASE1 PDAC RECRUITING NCT06922591
gemcitabine/nab-paclitaxel Other Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 Other Phase PHASE1 PDAC RECRUITING NCT06922591
TNG462 Other Phase PHASE1 PDAC RECRUITING NCT06922591
gemcitabine/nab-paclitaxel Other Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 Other Phase PHASE1 PDAC RECRUITING NCT06922591
TNG462 Other Phase PHASE1 PDAC RECRUITING NCT06922591
gemcitabine/nab-paclitaxel Other Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 Other Phase PHASE1 PDAC RECRUITING NCT06922591
TNG462 Other Phase PHASE1 PDAC RECRUITING NCT06922591
gemcitabine/nab-paclitaxel Other Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 Other Phase PHASE1 PDAC RECRUITING NCT06922591
TNG462 Other Phase PHASE1 PDAC RECRUITING NCT06922591
gemcitabine/nab-paclitaxel Other Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 Other Phase PHASE1 PDAC RECRUITING NCT06922591
TNG462 Other Phase PHASE1 PDAC RECRUITING NCT06922591
gemcitabine/nab-paclitaxel Other Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 Other Phase PHASE1 PDAC RECRUITING NCT06922591
TNG462 Other Phase PHASE1 PDAC RECRUITING NCT06922591
gemcitabine/nab-paclitaxel Other Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 Other Phase PHASE1 PDAC RECRUITING NCT06922591
TNG462 Other Phase PHASE1 PDAC RECRUITING NCT06922591
Pembrolizumab Other Phase PHASE1 Locally Advanced Solid Tumor RECRUITING NCT05732831
TNG462 Other Phase PHASE1 Locally Advanced Solid Tumor RECRUITING NCT05732831
gemcitabine/nab-paclitaxel Other Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 Other Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 Other Phase PHASE1 PDAC RECRUITING NCT06922591
TNG462 Other Phase PHASE1 PDAC RECRUITING NCT06922591
Pembrolizumab Other Phase PHASE1 Locally Advanced Solid Tumor RECRUITING NCT05732831
TNG462 Other Phase PHASE1 Locally Advanced Solid Tumor RECRUITING NCT05732831
Pembrolizumab Other Phase PHASE1 Locally Advanced Solid Tumor RECRUITING NCT05732831
TNG462 Other Phase PHASE1 Locally Advanced Solid Tumor RECRUITING NCT05732831
Pembrolizumab Other Phase PHASE1 Locally Advanced Solid Tumor RECRUITING NCT05732831
TNG462 Other Phase PHASE1 Locally Advanced Solid Tumor RECRUITING NCT05732831
Pembrolizumab Other Phase PHASE1 Locally Advanced Solid Tumor RECRUITING NCT05732831
TNG462 Other Phase PHASE1 Locally Advanced Solid Tumor RECRUITING NCT05732831
Pembrolizumab Other Phase PHASE1 Locally Advanced Solid Tumor RECRUITING NCT05732831
TNG462 Other Phase PHASE1 Locally Advanced Solid Tumor RECRUITING NCT05732831
Pembrolizumab Other Phase PHASE1 Locally Advanced Solid Tumor RECRUITING NCT05732831
TNG462 Other Phase PHASE1 Locally Advanced Solid Tumor RECRUITING NCT05732831
gemcitabine/nab-paclitaxel DRUG Phase PHASE1 PDAC RECRUITING NCT06922591
mFOLFIRINOX DRUG Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-6236 DRUG Phase PHASE1 PDAC RECRUITING NCT06922591
RMC-9805 DRUG Phase PHASE1 PDAC RECRUITING NCT06922591
abemaciclib DRUG Phase PHASE1 Non Small Cell Lung Cancer RECRUITING NCT06810544
TNG456 DRUG Phase PHASE1 Non Small Cell Lung Cancer RECRUITING NCT06810544
S095035 DRUG Phase PHASE1 MTAP-deleted Solid Tumors RECRUITING NCT06188702
Olaparib DRUG Phase PHASE1 Breast Cancer TERMINATED NCT06065059
TNG348 DRUG Phase PHASE1 Breast Cancer TERMINATED NCT06065059
TNG260 DRUG Phase PHASE1 Non Small Cell Lung Cancer RECRUITING NCT05887492
Pembrolizumab DRUG Phase PHASE1 Non Small Cell Lung Cancer RECRUITING NCT05887492
TNG462 DRUG Phase PHASE1 PDAC RECRUITING NCT06922591
TNG908 DRUG Phase PHASE1 Locally Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05275478
Total products: 123